Key result
Nonvitamin K antagonist oral anticoagulants affect routine and specialty coagulation assays, requiring specific assays to accurately quantitate their plasma concentrations.
Answers are grounded in this paper and cite their sources.
Provides guidance on understanding the impact of NOACs on laboratory coagulation assays and how to appropriately measure their concentrations.
Nonvitamin K antagonist oral anticoagulants (NOACs) are being used with increasing frequency due to their safety profile, ease of use, and given that therapeutic monitoring is not required. As these agents have only recently been FDA approved, their effect on routine and specialty coagulation assays is not well appreciated. This article discusses NOAC effect on routine coagulation assays and whether these assays can be used to estimate drug concentration as well as which assays are suitable to quantitate drug concentration in plasma. Also reviewed is the use of manufactured drug calibrators to determine reagent responsiveness and the effect of these agents on various special coagulation assays.
No takes yet. Share an insight, caveat, or question.
Gosselin et al. (2015) conducted a review in Anticoagulation therapy monitoring. Nonvitamin K antagonist oral anticoagulants (NOACs) was evaluated. Nonvitamin K antagonist oral anticoagulants affect routine and specialty coagulation assays, requiring specific assays to accurately quantitate their plasma concentrations.
Synapse has enriched 10 related papers. Consider them for comparative context: